Manuscripts
Showing 1554 manuscripts.
The Pharmacokinetics and Safety of Zidovudine in the Third Trimester of Pregnancy for Women Infected With Human Immunodeficiency Virus and Their Infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group Study (Protocol 082)
Citation
Mary Jo O'Sullivan. The Pharmacokinetics and Safety of Zidovudine in the Third Trimester of Pregnancy for Women Infected With Human Immunodeficiency Virus and Their Infants: Phase I Acquired Immunodeficiency Syndrome Clinical Trials Group Study (Protocol 082). American Journal of Obstetrics and Gynecology. 1993. 168: 1510-1516.Year
1993
Journal
American Journal of Obstetrics and Gynecology
Enhanced p24 Antigen Detection in Sera from HIV-Infected Children
Citation
E. Walter. Enhanced p24 Antigen Detection in Sera from HIV-Infected Children. Pediatric Infectious Disease Journal. 1993. 12: 94-96.Year
1993
Journal
Pediatric Infectious Disease Journal
Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117.
Citation
D. Richardson, Song-Heng Liou, James O. Kahn. Uric acid and didanosine compliance in AIDS clinical trials: an analysis of AIDS Clinical Trials Group protocols 116A and 116B/117.. Journal of Acquired Immune Deficiency Syndromes. 1993. 6: 1212-23.Year
1993
Journal
Journal of Acquired Immune Deficiency Syndromes
2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients
Citation
A. Berger, Joseph Arezzo, Herbert H. Schaumburg, Gail Skowron, Thomas C. Merigan, Sam Bozzette, Douglas D. Richman, Whaijen Soo. 2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology. 1993. 43: 358-62.Year
1993
Journal
Neurology
Human immunodeficiency virus infection in pregnant women under care at AIDS clinical trials centers in the United States
Citation
Pamela Stratton, Lynne M. Mofenson, Anne Willoughby. Human immunodeficiency virus infection in pregnant women under care at AIDS clinical trials centers in the United States. Obstetrics and Gynecology. 1993. 79: 364-8.Year
1993
Journal
Obstetrics and Gynecology
Potential of Population Pharmacokinetics to Reduce the Frequency of Blood Sampling Required for Estimating Kinetic Parameters in Neonates
Citation
L. Collart, Terrence F. Blaschke, F. Boucher, C. Prober. Potential of Population Pharmacokinetics to Reduce the Frequency of Blood Sampling Required for Estimating Kinetic Parameters in Neonates. Developmental Pharmacology and Therapeutics. 1992. 18: 71-80.Year
1992
Journal
Developmental Pharmacology and Therapeutics
Histoplasmosis - diagnosis and ,anagement
Citation
L. Joseph Wheat. Histoplasmosis - diagnosis and ,anagement. Infectious Diseases in Clinical Practice. 1992. 1: 287-90.Year
1992
Journal
Infectious Diseases in Clinical Practice
Diagnosis of histoplasmosis in patients with the acquired immunodeficiency syndrome by detection of Histoplasma capsulatum polysaccharide antigen in bronchoalveolar lavage fluid
Citation
L. Joseph Wheat, Patricia A. Connolly, Brian Williams, Kathleen Connolly, R. Blair, Marilyn S. Bartlett, Michelle M. Durkin. Diagnosis of histoplasmosis in patients with the acquired immunodeficiency syndrome by detection of Histoplasma capsulatum polysaccharide antigen in bronchoalveolar lavage fluid. American Review of Respiratory Diseases. 1992. 145: 1421-4.Year
1992
Journal
American Review of Respiratory Diseases
Immune Abnormalities and Control of AIDS
Citation
John L. Fahey. Immune Abnormalities and Control of AIDS. Progress in Allergy and Clinical Immunology. 1992. 2: 276-81.Year
1992
Journal
Progress in Allergy and Clinical Immunology
The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia
Citation
J. Mohle-Boetani, S. K. Akula, Mark Holodniy, David Katzenstein, Gabriel Garcia. The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia. Western Journal of Medicine. 1992. 156: 303-6.Year
1992
Journal
Western Journal of Medicine